July 8 (Reuters) - Genentech, a unit of Roche Group

, said on Monday it has re-launched its eye implant,

Susvimo, in the United States, following the end of a voluntary

recall, and the device will be available to patients in the

coming weeks.

The implant was approved by the U.S. health regulator in

2021 to treat a chronic disorder that caused blurred vision.

The following year, Genentech voluntarily recalled the

implant following test results that showed some implants did not

meet the company's performance standards.

Genentech has since updated the implants, and testing has

confirmed that they now meet the performance standards.

(Reporting by Sneha S K in Bengaluru; Editing by Shilpi

Majumdar and Shinjini Ganguli)